60.16 USD
-0.98 (-1.6%)
60.16 USD
0 (0%)
Overall BMRN gets a fundamental rating of 6 out of 10. We evaluated BMRN against 530 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making BMRN a very profitable company, without any liquidiy or solvency issues. BMRN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make BMRN suitable for value and quality investing!
1. Profitability
1.1 Basic Checks
In the past year BMRN was profitable.
In the past year BMRN had a positive cash flow from operations.
BMRN had positive earnings in 4 of the past 5 years.
BMRN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 6.83%, BMRN belongs to the best of the industry, outperforming 92.45% of the companies in the same industry.
BMRN has a Return On Equity of 8.59%. This is amongst the best in the industry. BMRN outperforms 92.08% of its industry peers.
Looking at the Return On Invested Capital, with a value of 7.69%, BMRN belongs to the top of the industry, outperforming 93.77% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 18.22%.
The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 16.82%, BMRN belongs to the top of the industry, outperforming 92.64% of the companies in the same industry.
The Operating Margin of BMRN (20.21%) is better than 94.53% of its industry peers.
BMRN's Gross Margin of 81.32% is amongst the best of the industry. BMRN outperforms 85.28% of its industry peers.
BMRN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
Compared to 5 years ago, BMRN has more shares outstanding
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
BMRN has an Altman-Z score of 5.65. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.65, BMRN is in the better half of the industry, outperforming 73.58% of the companies in the same industry.
BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.72, BMRN belongs to the top of the industry, outperforming 94.34% of the companies in the same industry.
BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 64.15% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.65 |
ROIC/WACC0.92
WACC8.33%
2.3 Liquidity
BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.83, BMRN perfoms like the industry average, outperforming 55.09% of the companies in the same industry.
A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a Quick ratio of 3.10. This is in the lower half of the industry: BMRN underperforms 61.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 52.00% over the past year.
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
The Revenue has been growing by 10.86% on average over the past years. This is quite good.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
The Earnings Per Share is expected to grow by 27.59% on average over the next years. This is a very strong growth
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.34% yearly.
EPS Next Y33.85%
EPS Next 2Y44.64%
EPS Next 3Y33.41%
EPS Next 5Y27.59%
Revenue Next Year12.52%
Revenue Next 2Y10.02%
Revenue Next 3Y9.15%
Revenue Next 5Y7.34%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 22.62 indicates a rather expensive valuation of BMRN.
BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 93.96% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.59. BMRN is around the same levels.
Based on the Price/Forward Earnings ratio of 13.01, the valuation of BMRN can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 97.17% of the companies listed in the same industry.
BMRN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.62 | ||
| Fwd PE | 13.01 |
4.2 Price Multiples
95.28% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
97.17% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14 | ||
| EV/EBITDA | 14.76 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 33.41% in the coming years.
PEG (NY)0.67
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y33.41%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
60.16
-0.98 (-1.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners97.86%
Inst Owner Change-1%
Ins Owners0.65%
Ins Owner Change-0.62%
Market Cap11.56B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts82.35
Price TargetN/A
Short Float %4.32%
Short Ratio2.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.86%
PT rev (3m)-5.31%
EPS NQ rev (1m)-2.16%
EPS NQ rev (3m)10.6%
EPS NY rev (1m)-2.6%
EPS NY rev (3m)-15.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.24%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.62 | ||
| Fwd PE | 13.01 | ||
| P/S | 3.74 | ||
| P/FCF | 14 | ||
| P/OCF | 12.65 | ||
| P/B | 1.91 | ||
| P/tB | 2.05 | ||
| EV/EBITDA | 14.76 |
EPS(TTM)2.66
EY4.42%
EPS(NY)4.62
Fwd EY7.68%
FCF(TTM)4.3
FCFY7.15%
OCF(TTM)4.76
OCFY7.91%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.67
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.65 |
F-Score8
WACC8.33%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y33.85%
EPS Next 2Y44.64%
EPS Next 3Y33.41%
EPS Next 5Y27.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.52%
Revenue Next 2Y10.02%
Revenue Next 3Y9.15%
Revenue Next 5Y7.34%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.31%
EBIT Next 3Y38.69%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
Can you provide the valuation status for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 33.85% in the next year.